3
Participants
Start Date
January 5, 2021
Primary Completion Date
July 15, 2022
Study Completion Date
September 20, 2022
Carboplatin
Carboplatin 5-6 mg/mL/min AUC will be delivered over 30 - 60 minutes intravenously on Day 1 of each 21 day Cycle after completion of atezolizumab. For 4 cycles.
Etoposide
Etoposide 80-100 mg/m2 will be delivered over 60 minutes intravenously on Days 1-3 of each 21 day Cycle after completion of carboplatin (Day 1 only). For 4 cycles.
Atezolizumab
Atezolizumab 1200 mg will be delivered over 60 (± 15) minutes intravenously on Day 1 of each 21 day Cycle for 4 cycles then continue as monotherapy maintenance with the same schedule.
Duke Cancer Institute, Durham
St. Vincent Anderson Regional Hospital, Anderson
University of Illinois Cancer Center, Chicago
Nebraska Methodist Hospital, Omaha
City of Hope, Duarte
Summit Health, Berkeley Heights
Collaborators (2)
Genentech, Inc.
INDUSTRY
Duke University
OTHER
Jeffrey Clarke
OTHER